Nexstim enters depression therapy market in Sweden
Helsinki, Finland: 10 May 2019 – Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), announces that its business partner PO Medica AB has sold two Navigated Brain Therapy (NBT®) systems to two different hospitals in Sweden.
Both hospitals will be the first in Sweden to have the NBT® systems and it will be their first time using navigated Transcranial Magnetic Stimulation (TMS) for the treatment of MDD. The systems will be used for the treatment of depression in patients who failed to respond to antidepressant medications.
More info on Nexstim’s website.